We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EDAN Takes its Solutions up a Notch at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)

EDAN Instruments, Inc. (Shenzhen, China) is demonstrating its range of latest innovations at MEDICA, the premiere global medical trade show being held at Dusseldorf, Germany, from Nov. 14 to 17, 2022. The company is presenting five new products to more than 120,000 visitors from over 150 countries at the world’s largest trade fair for the medical sector.

For the laboratory sector, EDAN is showcasing its combined range of POCT and IVD innovations at its booth this year, including the ClariLight CL30, its first molecular diagnostics solution. The ClariLight CL30 is a new point of care (POC) molecular diagnostics analysis system based on Loop-Mediated Isothermal Amplification (LAMP) that provides on-the-spot results and empowers physicians for early infectious disease diagnostics, thanks to its agility, speed and flexibility. ClariLight CL30 is designed to offer effective solutions for infectious disease diagnostics by reducing the window period. Unlike PCR-based methods (generally non-portable, laboratory setting, time-consuming), CL30 produces molecular results as quick as 15 minutes, while multi-parameters cartridges and the extraction-free procedure allow massive and rapid molecular tests feasible.

At MEDICA 2022, EDAN is also showcasing iX Series, its next-generation patient monitor that comes with a widescreen design and optimized workflow. Its innovative non-invasive technologies and selective clinical tools contribute to more efficient patient monitoring. Visitors to EDAN’s booth at MEDICA 2022 can experience two ready-to-launch products from the company, including the fully-automated electrocardiograph SE-1201 Pro, and the Holter ECG & ABP 2-in-1 wearables SA-20, tailored for the diagnosis of cardiogenic hypertension. In the obstetrics & gynecology area, EDAN is presenting its portable biofeedback and stimulation system, PA4 Pro, which allows physiotherapists to deliver pelvic floor muscular assessment and treatment flexibly in any scenario. For the first time, EDAN is also exhibiting the upgraded version of Acclarix LX9 alongside its technologically upgraded transducers.

"The highlight is our first molecular diagnostics solution, ClariLight CL30. We are glad to see that most clients are attracted by its rapid results as quick as 15 minutes," said Bo Wang, IVD & POCT Marketing Manager at EDAN.

"A rolling stone gathers no moss. Our breakthrough is visible," said Alex You, Senior Director of EDAN Global Marketing & Strategic Operations, after having a dialogue on EDAN's global development plan with Mr. Wolfram Nikolaus Diener, President & CEO of Messe Dusseldorf GmbH. "And we will go further with a steady stream to advance in our journey towards improving human living conditions."

Related Links:
EDAN Instruments, Inc.

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.